Community Research and Development Information Service - CORDIS

H2020

HYPERQTOTAL Report Summary

Project ID: 709835

Periodic Reporting for period 1 - HYPERQTOTAL (“Diagnosis of Ischemic Heart Disease by means of innovative and highly accurate high frequency QRS electrocardiogram analysis”)

Reporting period: 2016-02-01 to 2016-04-30

Summary of the context and overall objectives of the project

The main objective of this Feasibility Analysis was to study and evaluate the viability of HyperQTotal from a technical, commercial and financial point of view, our ultimate goal being the validation of the higher efficacy and diagnostic value of high frequency electrocardiogram (HF-ECG) analysis over conventional stress-ECG tests for Coronary Artery Disease (CAD) and consequent market launch.

We have conducted this feasibility analysis by contacting potential clients, partners and hospitals who could assist us in the execution of the clinical validation study that is foreseen in a consecutive Phase 2 project. Central issue in this feasibility analysis was the question how HyperQTotal could be commercially launched in the most optimal manner, considering the CAD diagnostics market and purchasing power by its stakeholders. Moreover, we have considered several business and revenue models.

An estimation of the cost-effectiveness of implementing HyperQTotal for diagnosis of CAD demonstrated a potential reduction of 13% in unnecessary cardiac imaging tests and of 4% in superfluous coronary angiography procedures. Additionally, indirect costs savings related to better prognosis should be considered as well as the social impact on patients and their families.

HyperQTotal can be implemented on half of the existing ECG-hardware available (about 60% of all currently used computer-based systems) and only involves software for collecting and analysing the HF-data of the ECG and converting this data into useful information for any cardiologist, who will only need short training in interpretation of the HF-QRS information. It will be offered primarily to cardiologists and hospitals on a Pay-per-Test basis by providing it as a cloud service.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

We have contacted various potential stakeholders whose involvement is of crucial importance, and hospitals and CROs who may assist us in the execution of the clinical validation study foreseen in a consecutive project. Central question in this feasibility analysis was how HyperQTotal can be commercially launched most optimally, considering the CAD market and purchasing power by its stakeholders. For this, we have considered several business and revenue models.
HyperQTotal can be implemented on half of the existing hardware being software for collecting and analysing HF-data of an ECG and converting it into useful information for any cardiologist, who will only need brief training in interpreting HF-QRS data. It will be offered primarily to cardiologists and hospitals on a Pay-per-Test basis.
We have prepared a work plan for future work, which includes the development of HyperQTotal´s new features and a clinical validation study to prove the superiority of HyperQTotal over its precessor, HyperQ, and regular ECG software.

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The cost-effectiveness of implementing HyperQTotal for diagnosis of CAD demonstrated a potential reduction of 13% in unnecessary cardiac imaging tests and of 4% in superfluous angiography procedures. Also, indirect costs savings related to better prognosis should be considered as well as the social impact on patients and their families.
After 5 years commercialization, we aim to have HyperQtotal operating 2 Million stress-ECG tests per year, which would create around €48 Million of revenues. This success would create up to 30 new positions in BSP Medical.
Our estimations forecast that improved sensitivity of HyperQTotal entails a 4% reduction in the incidence of acute coronary events, 5% reduction in heart failure and 5% reduction in mortality among CHD patients. Moreover, the potential immediate annual savings amount to €400 Million. We expect that 25% of these savings can be achieved in Europe, 40% in North America and 35% in the rest of the world, predominantly in Asia.
Future application of HyperQTotal also comprises portable ECG-systems and wearables for individuals.

Related information

Record Number: 190161 / Last updated on: 2016-11-08
Follow us on: RSS Facebook Twitter YouTube Managed by the EU Publications Office Top